Clinical trials: Malignant Tumor With Metastasis
Nasopharyngeal Carcinoma (NPC), Metastatic Nasopharyngeal Carcinoma
Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II Study
The RADIANCE trial plans to enroll patients with chemotherapy-ineligible de novo metastatic nasopharyngeal carcinoma (AJCC 9th edition, TxNxM1).
- Trial name
- RADIANCE (NCT07756190)
- Testing
- Sintilimab, ipilimumab, Radscopal Radiotherapy
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Sun Yat-sen University
HER2 Gene Mutation
IAH0968 in Combination With GC for the Treatment of HER2-Positive Unresectable Advanced/Metastatic Malignant Tumors
The study aims to evaluate the efficacy and safety of IAH0968 in combination with gemcitabine and cisplatin for the treatment of HER2-positive unresectable advanced/metastatic malignant tumors and cholangiocarcinoma.
- Trial name
- NCT05991518
- Testing
- Injection of IAH0968+Gemcitabine+Cisplatin, Gemcitabine+Cisplatin
- Where
- China
- Volunteers
- 136 people
- Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
Solid Tumor Cancer, PDAC
IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors
This is a multicenter, open-label, Phase Ib/II clinical study. The study includes Phase Ib-Dose Exploration Stage and Phase II - Efficacy Exploration and Determination Stage.
- Trial name
- NCT07441174
- Testing
- IN10018 in combination with RNK08954
- Where
- 14 sites in China
- Volunteers
- 92 people
- Sponsor
- InxMed (Shanghai) Co., Ltd.
Metastatic Pancreatic Cancer
MesoPher/Mitazalimab-combination Therapy in Metastatic Pancreatic Disease (REACtiVe-2 Trial)
Pancreatic cancer is expected to be the second leading cause of cancer-related death in 2020. Pancreatic cancer is known as an immunological cold tumor.
- Trial name
- REACtiVe-2 (NCT05650918)
- Testing
- MesoPher, Mitazalimab
- Where
- Netherlands
- Volunteers
- 22 people
- Sponsor
- Joachim Aerts, MD PhD
Metastatic Pancreatic Adenocarcinoma, Refractory Malignant Solid Neoplasm
Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer
This partially randomized phase I trial studies the side effects and best dose of disulfiram when given together with chemotherapy in treating patients with a solid tumor that does not respond to treatment (refractory) or…
- Conditions
- Metastatic Pancreatic Adenocarcinoma, Refractory Malignant Solid Neoplasm, Stage IV Pancreatic Cancer AJCC v8
- Trial name
- NCT02671890
- Testing
- Chemotherapy, Disulfiram, Gemcitabine Hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Mayo Clinic
Carcinoma of Unknown Primary, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer
This trial uses blood tests and questionnaires to study how well participants with head and neck cancer that has spread to other places in the body adhere to swallowing exercises to prevent future disease.
- Conditions
- Carcinoma of Unknown Primary, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Trial name
- NCT03010150
- Testing
- Biospecimen Collection, Questionnaire Administration
- Where
- United States
- Volunteers
- 471 people
- Sponsor
- M.D. Anderson Cancer Center
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-[18F] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00935090
- Testing
- 3'-deoxy-3'-[18F]fluorothymidine
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Colorectal Cancer
Metastatic Colorectal Cancer Treated With Regorafenib and FOLFIRI
The survey is a retrospective study to evaluate the prognotic value of EGFR expression, KRAS mutations and tumor sideness in patients with metastatic colorectal cancer treated with regorafenib and FOLFIRI as a third- or…
- Trial name
- NCT03698253
- Testing
- Regorafenib, UGT1A1 genotyping (TA6/TA6), UGT1A1 genotyping (TA6/TA7)
- Where
- Taiwan
- Volunteers
- 41 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
BRCA1 Gene Mutation, BRCA2 Gene Mutation
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
This phase II trial studies how well pembrolizumab works in treating participants with cancer that has spread to other places in the body, has come back or has spread to nearby tissues or lymph nodes.
- Conditions
- BRCA1 Gene Mutation, BRCA2 Gene Mutation, Locally Advanced Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT03428802
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Rutgers, The State University of New Jersey
Advanced Malignant Mesothelioma, Extensive Stage Small Cell Lung Cancer
Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body
This pilot clinical trial studies the side effects of cryotherapy (cryoablation [CA]) in treating patients with lung cancer. Cryotherapy kills cancer cells by freezing them.
- Conditions
- Advanced Malignant Mesothelioma, Extensive Stage Small Cell Lung Cancer, Lung Metastases, Recurrent Malignant Mesothelioma
- Trial name
- NCT01325753
- Testing
- cryotherapy, quality-of-life assessment
- Sponsor
- Wake Forest University Health Sciences
Lung Carcinoma, Lung Non-Small Cell Carcinoma
Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study
This phase II trial tests the effectiveness and safety of artificial intelligence (AI) to determine dose recommendation during stereotactic body radiation therapy (SBRT) planning in patients with primary lung cancer or tumors…
- Conditions
- Lung Carcinoma, Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Lung, Stage I Lung Cancer AJCC v8
- Trial name
- NCT05802186
- Testing
- Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Northwestern University
Breast Neoplasm Female, Breast Cancer
Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients
The goal of this protocol is to evaluate the safety and efficacy of an alternative systemic combination approach that omits or delays the use of chemotherapy in metastatic disease, while improving efficacy and durability of…
- Conditions
- Breast Neoplasm Female, Breast Cancer, Breast Carcinoma, Breast Tumor
- Trial name
- NCT03650894
- Testing
- Nivolumab, Ipilimumab, Bicalutamide
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Providence Health & Services
Pheochromocytoma, Paraganglioma
ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid
The purpose of this study is to test the safety of a drug called Ultratrace iobenguane I 131 that has radioactivity, to measure how long it takes for the drug to be absorbed and passed out of the body, and to measure how much…
- Conditions
- Pheochromocytoma, Paraganglioma, Carcinoid
- Trial name
- NCT00339131
- Testing
- Ultratrace iobenguane I 131
- Volunteers
- 24 people
- Sponsor
- Molecular Insight Pharmaceuticals, Inc.
Brain Tumor
FBY PET/CT in Patients With Brain Tumors
This study is an open-labeled phase II diagnostic clinical trial to explore the safety and clinical value of FBY in suspected adult brain tumor patients.
- Trial name
- NCT03980431
- Testing
- FBY PET Examination
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking Union Medical College Hospital
Lung Carcinoma, Malignant Respiratory Tract Neoplasm
Continuous Positive Airway Pressure Device or Deep Inspiration Breath Hold in Reducing Tumor Motion in Patients Undergoing Stereotactic Body Radiation Therapy for Lung Cancer
This pilot phase I/II trial studies how well a continuous positive airway pressure device or deep inspiration breath hold works in reducing tumor movement in patients undergoing stereotactic body radiation therapy (SBRT) for lung…
- Conditions
- Lung Carcinoma, Malignant Respiratory Tract Neoplasm, Metastatic Malignant Neoplasm in the Lung
- Trial name
- NCT03422302
- Testing
- Biphasic Positive Airway Pressure, Computed Tomography, Continuous Positive Airway Pressure
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Solid Neoplasm, Lymphoma
Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants
This Phase 1, open-label, multicenter, 2-arm study was designed to evaluate SYNB1891 when administered either as monotherapy (Arm 1) or in combination with atezolizumab (Arm 2) in participants with advanced/metastatic solid…
- Trial name
- NCT04167137
- Testing
- SYNB1891, Atezolizumab
- Where
- 6 sites in United States
- Volunteers
- 32 people
- Sponsor
- Synlogic
Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma
Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma
This phase II trial studies how well dinutuximab works when given with sargramostim in treating patients with osteosarcoma that has come back after treatment (recurrent).
- Conditions
- Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma, Recurrent Osteosarcoma
- Trial name
- NCT02484443
- Testing
- Dinutuximab, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 130 sites in United States, Australia and 3 more
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Rectal Cancer, Adenocarcinoma, Rectal Cancer Stage II
"Oncologic Results and Risk Factors for Recurrence in Patients With Locally Advanced Rectal Cancer and Pathologic Complete Response After Neoadjuvant Treatment. Results From an Observational Retrospective Multicenter Long-term Follow-up Study".
Pathologic complete response (pCR) after multimodal treatment for locally advanced rectal cancer (LARC) patients is considered as the gold-standard of treatment success as it is associated to privileged oncologic outcome.
- Conditions
- Rectal Cancer, Adenocarcinoma, Rectal Cancer Stage II, Rectal Cancer Stage III, Distant Metastasis
- Trial name
- NCT05495308
- Testing
- neoadjuvant treatment
- Where
- Spain
- Volunteers
- 4 people
- Sponsor
- Hospital San Carlos, Madrid
Solid Tumor
A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors
The purpose of this study is to evaluate the safety and effectiveness of Nivolumab in combination with Ipilimumab in Chinese participants with previously treated late stage cancer.
- Trial name
- NCT03195478
- Testing
- Nivolumab, Ipilimumab
- Where
- 12 sites in China
- Volunteers
- 37 people
- Sponsor
- Bristol-Myers Squibb
Non Small Cell Lung Cancer
DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)
This study is designed to evaluate safety and antitumor activity of DZD6008 combination therapy in patients with advanced Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutations.
- Trial name
- NCT07070440
- Testing
- DZD6008, Pemetrexed, Carboplatin
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Dizal Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.